Sale20 Jun 2025, 12:18 pm
Cohance Lifesciences to Sell CR Bio Unit for Rs. 16 Crore
AI Summary
Cohance Lifesciences Ltd has entered into an agreement with Chromo Laboratories India Private Limited for the sale of its standalone Clinical Research and Bio-analytical unit (CR Bio) for a consideration of Rs. 16 crore. The CR Bio unit, which represents a non-core legacy asset, contributed approximately 0.82% to the Company’s standalone revenue in FY2025. The transaction is expected to complete in Q2 FY2026, subject to satisfaction of customary closing conditions.
Key Highlights
- Sale of CR Bio unit for Rs. 16 Crore
- CR Bio contributes 0.82% to the Company’s standalone revenue in FY2025
- Expected to complete in Q2 FY2026
- Transaction executed at arm’s length
- Outside the Scheme of Arrangement